A recent study reveals that patients who discontinue new slimming jabs like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt conventional diet and exercise programs.
Findings released in a major health publication points out that while obese people can lose about a fifth of their body weight while on the medication, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users using such medications should be informed of the potential of quick rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to starting mass within about a year and a half.
Analyzing Treatments
The research, which reviewed 37 of studies involving over 9,000 of patients, contrasted the effects of these new drugs with other pills.
The team point out that people who lose weight through diet and exercise generally experience a more gradual creep back—around 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Doctors believe the way of the jabs explains the amplified regain.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this medication leads to hunger is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
The NHS recommend the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians say that, given the likelihood of weight regain, the therapy is often long-term.
This opinion is echoed by pharmaceutical companies, who say that the findings "underscore the long-term nature of obesity," akin to managing conditions like high blood pressure.
User Experiences
People who have stopped the medication describe a powerful resurgence of appetite.
"It felt as if a switch that goes on and you become extremely hungry," described an individual.
This challenge is exacerbated if patients have not developed sustainable dietary or behavioural modifications during therapy.
Significant Use
Survey data indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Use is greater among women compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while the jabs are powerful agents for shedding pounds, they are not a standalone solution and lasting health benefits relies on ongoing lifestyle support.
